NICE says no to Merck Serono’s Bavencio in bladder cancerMerck Serono’s Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer Share XNICE says no to Merck Serono’s Bavencio in bladder cancerhttps://pharmaphorum.com/news/nice-says-no-to-merck-seronos-bavencio-in-bladder-cancer/
Janssen files its first CAR-T therapy cilta-cel in EuropeJohnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, Share XJanssen files its first CAR-T therapy cilta-cel in Europehttps://pharmaphorum.com/news/janssen-files-its-first-car-t-therapy-cilta-cel-in-europe/
Keytruda should lose stomach cancer indication, says ODACThe FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co’s Keytruda of its accelerated Share XKeytruda should lose stomach cancer indication, says ODAChttps://pharmaphorum.com/news/keytruda-should-lose-stomach-cancer-indication-says-odac/
FDA looks at pulling speedy approvals for three cancer drugsFDA advisors will scrutinise three cancer immunotherapies granted conditional approvals at a three-day meeting this week, to see Share XFDA looks at pulling speedy approvals for three cancer drugshttps://pharmaphorum.com/news/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs/
Exscientia starts trials of first AI-derived cancer immunotherapyExscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) Share XExscientia starts trials of first AI-derived cancer immunotherapyhttps://pharmaphorum.com/news/exscientia-starts-trials-of-first-ai-derived-cancer-immunotherapy/
Cancer Research UK spinout Achilles raises $175.5m in IPOUK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that Share XCancer Research UK spinout Achilles raises $175.5m in IPOhttps://pharmaphorum.com/news/cancer-research-uk-spinout-achilles-raises-175-5m-in-ipo/
Pyxis follows Pfizer alliance with $152m fundraising for cancer pipelineFresh from a licensing agreement with Pfizer, US startup Pyxis Oncology has raised a sizeable $152 million in Share XPyxis follows Pfizer alliance with $152m fundraising for cancer pipelinehttps://pharmaphorum.com/news/pyxis-follows-pfizer-alliance-with-152m-fundraising-for-cancer-pipeline/
Merck gets confirmatory trial win for Keytruda in endometrial cancerMerck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a Share XMerck gets confirmatory trial win for Keytruda in endometrial cancerhttps://pharmaphorum.com/news/merck-gets-confirmatory-trial-win-for-keytruda-in-endometrial-cancer/
GSK’s big-ticket cancer alliance with Merck KGaA stumbles againMerck KGaA’s bispecific cancer candidate bintrafusp alfa has failed a second clinical trial in the space of a Share XGSK’s big-ticket cancer alliance with Merck KGaA stumbles againhttps://pharmaphorum.com/news/gsks-big-ticket-cancer-alliance-with-merck-kgaa-hits-another-hurdle/
